# US 8,785,375 B2 · Cyclic antimicrobial peptides for treating bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,375 B2
- Document ID: US8785375B2
- Status: Granted
- Kind: B2
- Application number: 13/592,246
- Filed: 2012-08-22
- Published: 2012-12-13
- Granted: 2014-07-22
- Earliest claimed: 2005-12-22
- Assignees: Novabiotics Limited
- Applicants: Deborah O'Neil
- Inventors: Deborah O'Neil
- Web page: https://patentgrep.com/patent/US8785375B2

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.

## Claims

### Claim 1

A composition consisting of a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the cyclic peptide comprises from 5 to 13 contiguous arginine residues.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the cyclic peptide comprises from 4 to 7 contiguous arginine residues.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the cyclic peptide comprises 7 contiguous arginine residues.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the arginine residues are D-amino acids.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the arginine residues are L-amino acids.

### Claim 6

A composition consisting of a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the cyclic peptide consists of 7 arginine residues.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the arginine residues are D-amino acids.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the arginine residues are L-amino acids.

### Claim 9 (depends on 1)

A method of treating a bacterial infection in a subject, wherein the bacterial infection is selected from a group consisting of: Staphylococcus spp., Pseudomonas spp., Cryptococcus spp., and E. coli, comprising administering to the subject a therapeutically effective amount of a composition of claim 1.

### Claim 10 (depends on 6)

A method of treating a bacterial infection in a subject, wherein the bacterial infection is selected from a group consisting of: Staphylococcus spp., Pseudomonas spp., Cryptococcus spp., and E. coli, comprising administering to the subject a therapeutically effective amount of a composition of claim 6.